NCT05205850View on ClinicalTrials.gov

A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 1, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

RC118-ADC

RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor

Trial Locations (2)

310009

NOT_YET_RECRUITING

The first affiliated hospital, zhejiang universtity school of medicine, Hangzhou

Unknown

RECRUITING

Zhongshan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY